The Role of Precision Medicine in the Cancer biomarker Market
Precision medicine is at the heart of the Cancer biomarker Market. Biomarkers help oncologists tailor therapies based on individual genetic profiles, ensuring that patients receive the most effective treatments with minimal side effects.
Biomarker-driven precision medicine is particularly important in cancers such as breast, lung, and colorectal, where genetic variations influence treatment responses. As clinical adoption increases, biomarkers are becoming standard tools in oncology practice.
Market Outlook: The cancer biomarker market was valued at USD 15.9 billion in 2022 and is projected to reach USD 27.8 billion by 2030, expanding at a 9.8% CAGR.